血脂异常与老年冠心病患者冠脉病变程度的相关性研究

目的 探讨血脂异常与老年冠心病患者冠脉病变程度的相关性。方法 选取2015年5月~2017年1月本院心内科住院的明确诊断为冠状动脉粥样硬化性心脏病（CHD）的150例老年患者设为CHD组。选取同期收治的150例非CHD患者为对照组。比较两组血清中总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）水平,并计算N-HDL-C、LDL-C/N-HDL-C、LDL-C/HDL-C、TC/HDL-C、TG/HDL-C值。比较不同冠脉病变支数、不同病情严重程度的CHD患者的血脂及其比值。对血脂与冠脉病变支数、病情严重程度积分进行相关性分析。结果 CHD组患者LDL-C、TG、TC、N-HDL-C水平、LDL-C/HDL-C、TC/HDL-C、TG/HDL-C值均高于对照组,HDL-C水平低于对照组,差异均有统计学意义（P＜0.05）;不同冠脉病变支数各亚组间的TC、TG、N-HDL-C水平、TC/HDL-C比值差异存在统计学意义（P＜0.05）;TC、TG、N-HDL-C水平、TC/HDL-C比值均与冠脉病变支数均呈正相关（P＜0.05）;不同病情严重程度亚组间的LDL-C、TC、TG、N-HDL-C水平、LDL-C/HDL-C、TC/HDL-C、TG/HDL-C比值差异存在统计学意义（P＜0.05）;CHD患者LDL-C、TC、TG、N-HDL-C水平、LDL-C/HDL-C、TC/HDL-C、TG/HDL-C比值与冠状动脉病变积分均呈正相关（P＜0.05）。结论 可以通过对血脂指标的监测,并计算N-HDL-C、TC/HDL-C、LDL-C/HDL-C、TC/HDL-C、TG/HDL-C值,来评估CHD病情的临床进展。     

健康成年女性内生雌激素的变化与脂类代谢关系的探讨

目的:研究健康成年女性内生雌激素的变化对脂类代谢的影响,为雌激素替代治疗(ERT)提供参考.方法:选择健康体检育龄妇女387例,年龄(21～50)岁,测定雌激素(E2)、孕激素(P)、载脂蛋白A-Ⅰ(apoA-Ⅰ)、载脂蛋白B(apoB)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、甘油三酯(TG)、脂蛋白a[LP(a)].并从中选取40例自愿者作月经周期中自体早排卵期(EF)和黄体期(LUT)对照.结果:月经周期中雌激素的周期性波动,会影响到脂类代谢,选取EF、LUT作配对比较,发现内生雌激素水平对apoA-Ⅰ、apoB、apoA-Ⅰ/apoB、HDL-C、LDL-C、LDL-C/HDL-C、TC、TC/HDL-C、TG有影响,对LP(a)无影响,其中LDL-C、LDL-C/HDL-C、TC/HDL-C水平在LUT均比EF明显低(P＜0.05).结论:健康成年女性月经周期中内生雌激素的波动对脂类代谢有影响,虽然对于多数脂类影响不显著,但对在绝经期前女性进行脂类检测和药物治疗监测时,对测定结果处于临界水平的标本,需将其考虑为重要影响因素之一,不注意这些波动可能会影响治疗和诊断.随年龄增长呈周期性变化的雌激素水平有下降趋势,脂类:TC、TG、LDL-C、apoB随年龄增长有增长趋势,作为心血管疾病的危险因素之一,是一个较长的渐进过程.     

健康体检者胰岛素抵抗与血脂异常的相关性及血脂最佳分界值的探讨

目的 分析健康体检者胰岛素抵抗（IR）与脂代谢异常之间的相关性,并探讨应用甘油三酯/高密度脂蛋白胆固醇（TG/HDL-C）预测IR的最佳分界值。方法 选取2014年5月~7月于河北省人民医院体检中心体检者785名纳入本研究,按照不同性别将研究对象分别以胰岛素抵抗指数（HOMA-IR）中位数2.02为界限,分为胰岛素抵抗（IR）组和胰岛素敏感（IS）组,比较两组体格检查指标及生化指标,并分析IR与血脂异常的相关性。应用ROC曲线探讨TG/HDL-C预测IR的最佳分界值。 结果 两组男性和女性空腹血糖（FBG）、总胆固醇（TC）、TG、HDL-C、低密度脂蛋白胆固醇（LDL-C）水平及TG/HDL-C比较,差异有统计学意义（P＜0.05）。Spearman相关分析显示,HOMA-IR与FBG、TC、TG、LDL-C、TG/HDL-C呈正相关（P＜0.05）,与HDL-C呈负相关（P＜0.05）。Logistic回归分析结果显示年龄、体重指数（BMI）、腰围（WC）、FBG、TG及HDL-C是IR的危险因素。ROC曲线结果提示预测男性健康体检者IR发生风险的TG/HDL-C为1.24（AUC:0.748,95%CI:0.704~0.792）,敏感性为64.80%,特异性为75.90%;预测女性健康体检者IR发生风险的TG/HDL-C为1.36（AUC:0.728,95%CI:0.670~0.785）,敏感性为58.00%,特异性为79.70%。结论 IR与血脂异常具有相关性,尤其和TG、HDL-C密切相关。TG/HDL-C可以作为预测健康体检者IR的一个指标。     

布加综合征有关生化指标的病例对照研究

目的 通过分析布加综合征有关主要生化指标的特点,为了解BCS患者血栓形成的因素提供线索。方法 收集我院2017年2月~2018年1月住院治疗的105例BCS作为病例组,选取同期来本院体检中心体检的同性别、同年龄的105例健康体检者为对照组。采用病例对照研究,对两组WBC、RBC、HGB、MCH、Neu%、Lym%、PLT、TC、TG、HDL-C及LDL-C各指标分别进行男女分层分析。结果 病例组男性患者的WBC、HGB、MCH、Lym%、PLT、TC、TG、HDL-C及LDL-C水平与对照组比较,差异有统计学意义（P＜0.05）;两组男性患者RBC及Neu%比较,差异无统计学意义（P＞0.05）。病例组女性患者的WBC、HGB、MCH、Lym%、PLT、TC、TG、LDL-C水平与对照组比较,差异有统计学意义（P＜0.05）;两组女性患者RBC、Neu%及HDL-C水平比较,差异无统计学意义（P＞0.05）。结论 加强与血栓形成有密切关系的如PLT、TC、TG、HDL-C及LDL-C等指标的基础研究,为BCS的病因研究及有针对性的治疗提供科学依据。     

武汉地区女性血清E2水平及绝经年龄的调查

目的：探讨武汉市城区各年龄段女性血清雌二醇（E2）水平及绝经年龄,为临床上雌激素相关疾病预防和治疗以及女性保健提供科学依据。方法：筛选武汉市区（26～75）岁健康、无内分泌及生殖系统疾病女性2020例,运用核医学体外分析技术,对研究对象的血液标本中E2进行测定,运用spss13.0进行统计分析,得出武汉地区女性各年龄段E2水平及分布情况、女性E2的正常值参考范围和绝经年龄。结果：①武汉地区女性血清E2水平在（31～35）岁年龄组达峰值,以后逐步下降,在（46～50）岁组明显下降,而在（51～55）岁组阶段下降幅度最大;②武汉地区女性平均绝经年龄为48.08岁。结论：武汉地区女性绝经年龄有所提前,与1989年全国水平相比平均提前了2.3岁,女性保健工作应该引起重视。     

糖耐量异常患者血清癌胚抗原相关细胞黏附分子1与 动脉粥样硬化的关系

目的 探讨血清癌胚抗原相关细胞粘附分子1（CEACAM1）与糖耐量异常（IGT）患者合并颈动脉粥样硬化（CAS）的相关性。方法 选取2015年10月~2017年10月我院收治的IGT患者80例,根据颈动脉彩色多普勒超声结果分为IGT组44例和IGT+CAS组36例,另选取同期我院健康体检者30名作为正常对照组（NGT组）,比较三组临床指标（TG、TC、LDL-C等）,分析血清CEACAM1与临床指标的相关性及其影响因素。结果 三组年龄、性别、BMI、SBP、DBP比较,差异无统计学意义（P＞0.05）。IGT组和IGT+CAS组TG、TC、LDL-C、FBG、HbA1c、FINS、HOMA-IR、hs-CRP、IL-6、TNF-α均高于NGT组,HDL-C低于NGT组,差异有统计学意义（P＜0.05）;IGT+CAS组TG、TC、LDL-C、FBG、FINS、HOMA-IR、IL-6、TNF-α高于IGT组,HbA1c、HDL-C低于IGT组,差异有统计学意义（P＜0.05）。IGT+CAS组、IGT组CEACAM1水平低于NGT组,IGT+CAS组CEACAM1水平低于IGT组,IGT组CEACAM1水平低于NGT组,差异有统计学意义（P＜0.05）。Pearson相关性分析表明,IGT患者血清CEACAM1与TC、LDL-C、FBG、HbA1c、FINS、HOMA-IR呈负相关,与HDL-C呈正相关（P＜0.05）;与年龄、BMI、SBP、DBP、TG、hs-CRP、IL-6、TNF-α无相关性（P＞0.05）。多元线性回归结果显示,TC、HDL-C和HbA1c是血清CEACAM1的独立影响因素。结论 CEACAM1可能与IGT的发生发展有关;CEACAM1水平降低,可能是IGT患者CAS发生发展的原因之一。     

急性心肌梗死冠脉病变严重程度与骨桥蛋白的相关性分析

目的 探讨急性心肌梗死（AMI）冠脉严重程度与骨桥蛋白（OPN）的相关性。方法 回顾性分析2016年9月~2017年12月我院收治的急性心肌梗死患者127例,根据OPN水平分为高OPN组65例和低OPN组62例,比较两组患者基础资料及多元线性分析OPN与冠脉严重程度的影响因素。结果 两组年龄、TG、TC、HDL-C、LDL-C及Gensini积分比较,差异有统计学意义（P＜0.05）;两组性别、既往史、左室射血分数、药物治疗比较,差异无统计学意义（P＞0.05）。多元线性回归结果表明,OPN、年龄、LDL-C和HDL-C为Genisi积分的独立影响因素。结论 OPN与AMI患者冠脉病变严重程度独立相关,可评估急性心肌梗死冠脉病变严重程度。     

2型糖尿病周围神经病变与血清促甲状腺激素关系的研究

目的 分析2型糖尿病（T2DM）患者周围神经病变与血清促甲状腺激素（TSH）水平的关系。方法 选择329例柳州市人民医院内分泌科住院T2DM患者进行横断面研究,按照有无神经病变分为糖尿病周围神经病变（DPN）组193例和无糖尿病周围神经病变（NDPN）组136例。收集所有患者临床资料,检测两组患者HbAlc、TC、TG、HDL-C、LDL-C、TSH水平。结果 两组HbAlc、TC、HDL-C、LDL-C、TSH组间比较,差异无统计学意义（P＞0.05）;DPN组年龄大于NDPN组,糖尿病病程长于NDPN组,统计学意义显著（P＜0.01）;DPN组TG水平低于NDPN组,差异有统计学意义（P＜0.05）。Logistic回归分析发现,HbA1c、病程及年龄进入最终回归方程[OR=1.170,95%CI:1.048~1.305（HbA1c）;OR=1.059,95%CI:1.013~1.108（病程）;OR=1.043,95%CI:1.015~1.072（年龄）],HbA1c、病程及年龄是DPN发生的危险因素。结论 HbA1c、病程及年龄是DPN发生的危险因素,住院T2DM患者DPN与血清TSH水平无明显相关。     

2型糖尿病合并抑郁障碍患者C反应蛋白和血脂检测的意义

目的观察2型糖尿病合并抑郁障碍患者C反应蛋白（CRP）和血脂的变化。方法根据汉密顿抑郁量表（HAMD）测定结果将85例2型糖尿病患者分为抑郁障碍组和非抑郁障碍组。测定两组患者空腹血糖（FPG）、空腹胰岛素（FINS）、三酰甘油（TG）、总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）和CRP，并计算胰岛素抵抗指数（HOMA-IR）。结果抑郁障碍组FPG、CRP、TG、TC、LDL-C、FINS和HOMA-IR比非抑郁障碍组高、HDL-C比非抑郁障碍组低，其中FPG、CRP、TG、TC和HOMA-IR差异有统计学意义（P〈0．05）。结论检测合并抑郁障碍2型糖尿病患者CRP和血脂对早期干预、指导治疗有一定的临床价值。     

溃疡性结肠炎患者血清性激素及脂蛋白测定的临床意义

目的：研究溃疡性结肠炎（ulcerative colitis,UC）患者血清蛋白质和脂代谢异常与性激素水平异常的关系。方法：分别测定72例UC组和72例健康对照组血清雌二醇（E2）、睾酮（T）、孕酮（P）、泌乳素（PRL）、促黄体生成素（LH）、促卵泡激素（FSH）及血清总蛋白（TP）、白蛋白（Alb）、球蛋白（G）、白球比（A/G）、总胆固醇（TC）、高密度脂蛋白（HDL-C）、低密度脂蛋白（LDL-C）水平,并对其进行相关分析。性激素测定时对照组采用年龄、性别和卵巢周期与病例组1 1配对的原则。结果：UC患者血清T、LH、FSH、TB、Alb、A/G、TC、LDL-C水平显著低于正常对照组（P〈0.01）;血清E2、PRL水平显著高于正常对照组（P〈0.01）。相关分析表明,UC患者E2与TB、A/G、TC之间存在高度负相关（P〈0.01）;T与TC、TB之间存在高度正相关（P〈0.01）。女性E2与LH、FSH之间无相关性（P〉0.05）,男性T与LH、FSH之间亦无相关性（P〉0.05）。结论：UC患者存在脂蛋白及性激素水平代谢异常,血清性激素水平异常影响患者脂蛋白的水平代谢。测定血清性激素水平可为临床提供新的治疗思路。     

Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS

BACKGROUND: Decreased high-density lipoprotein cholesterol (HDL-C) and sex hormone-binding globulin (SHBG) levels, and the metabolic syndrome, are all closely associated with a higher prevalence of atherosclerotic cardiovascular disease. We investigated the association between HDL-C, SHBG and the metabolic syndrome in women with polycystic ovary syndrome (PCOS). METHODS AND RESULTS: Among 106 young Taiwanese women (mean age +/- SD, 24.9 +/- 4.8 years) with PCOS, 69 (65.1%) women had an HDL-C level <50 mg dl(-1). The level of HDL-C was highly correlated with that of serum SHBG (gamma = 0.6034, P < 0.0001). The SHBG level was significantly lower in subjects with an HDL-C <50 mg dl(-1) than that in subjects with an HDL-C > or =50 mg dl(-1). Using multiple linear regression models with adjustment for age, BMI and other anthropometric, metabolic, liver function and hormonal variables, we showed serum SHBG to be independently correlated with HDL-C. Based on logistic regression analysis with adjustment for age, the SHBG level was significantly lower in women with PCOS with the metabolic syndrome (odds ratio = 0.92, P = 0.003). CONCLUSIONS: Low levels of SHBG in women with PCOS were associated with low levels of HDL-C, independent of insulin resistance and obesity. The SHBG level was inversely related to the occurrence of metabolic syndrome, further strengthening the potential link between SHBG levels and cardiovascular disease in women with PCOS.     

The influence of apo E phenotypes on the plasma triglycerides response to hormonal replacement therapy during the menopause.

OBJECTIVE: To study the influence of apo E phenotype in plasma lipids, especially in triglycerides levels, in menopausal women receiving hormonal replacement therapy (HRT). METHODS: One hundred and ten postmenopausal women were studied. Plasma total cholesterol (TC), HDL-C and triglycerides (TG) were measured before and after 3 months of HRT and the apo E phenotype was determined. According to the apo E phenotype the sample was divided into three groups: E2/E3 (n=28), E3/E3 (n=96) and E4/E3 (n=25). RESULTS: In the pre-treatment state, higher plasma levels of TC and TC/HDL-C ratio were observed in women with phenotype E3/E4 (P<0.0001 and P<0.02, respectively), while higher plasma TG levels were found in the apo E2/E3 group (P<0.0001). After HRT, women with phenotype E3/E4 showed higher levels of TC and TC/HDL-C ratio (P<0.0001 and P<0.006, respectively). The apo E2/E3 phenotype group showed increased levels of TG (P<0.0001). In the multivariant analysis the changes of TG after HRT were related to the type of treatment used (P<0.001), age (P=0.05) and the apo E phenotype (E2/E3). CONCLUSION: Women with phenotype E2/E3 have higher plasma TG levels and show a significant post HRT increase compared with the other phenotypes. Other factors with a lower impact on TG levels are age and progestagen association.     

Elevated sex-hormone binding globulin in elderly women with Alzheimer's disease

BACKGROUND: Hormone levels change significantly with increasing age. These changes may be related to, or be associated with, the emergence of age-related diseases, such as Alzheimer's disease (AD). METHODS: Five hundred and seventy-six women over the age of 65 were studied from the Washington Heights-Inwood Columbia Aging Project (WHICAP). These women were selected from a group of healthy Medicare beneficiaries that were aged 65 and older living in the geographically defined area of northern Manhattan in New York City. Serum levels of estrone (E1), estradiol (E2), total testosterone (TT), dehydroepiandosterone (DHEA), luteinizing hormone (LH), follicle stimulating hormone (FSH), and sex-hormone binding globulin (SHBG) were measured. RESULTS: Significant differences were found between patients with AD and controls only in the level of SHBG, which was 20% higher in patients compared to controls (68.5nmol/l versus 54.7nmol/l, P<0.001). We also estimated levels of total E2 because after menopause, E2 is largely derived from E1. AD patients had significantly lower levels of estimated E2 (AD 0.46 versus controls 0.49, P<0.01). Differences remained significant after adjusting for age, ethnic group, education, and body mass index (BMI). CONCLUSIONS: A marked increase in SHBG levels was found in AD patients. SHBG normally responds to circulating testosterone and estrogen, therefore, elevated SHBG suggests an abnormal increase in its production and regulation. Further work is needed to clarify the cause and consequences of this observation.     

Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene

OBJECTIVE: To assess endogenous androgen and insulin resistance status in postmenopausal women receiving continuous combined hormone therapy (HT), tibolone, raloxifene or no therapy. METHODS: A total of 427 postmenopausal women aged 42-71 years were studied in a cross-sectional design. Among them 84 were taking HT (46 women conjugated equine estrogens 0.625 mg; medroxyprogesterone acetate, 5 mg, CEE/MPA; and 38 women 17beta-estradiol 2 mg; norethisterone acetate 1 mg, E2/NETA); 83 were taking tibolone 2.5 mg; 50 were taking raloxifene HCl 60 mg; and 210 women were not receiving any therapy. Main outcome measures were FSH, LH, estradiol, total testosterone, SHBG, free androgen index (FAI), Delta4-Androstendione (Delta4-A), Dehydroepiandrosterone sulphate (DHEAS) and HOMA insulin resistance index (HOMA-IR). RESULTS: In women not on hormone therapy smoking and older age was associated with lower DHEAS levels. FAI values increased linearly with increasing BMI. Age and BMI were positive determinants of HOMA-IR, while no association was identified between endogenous sex steroids and insulin resistance. CEE/MPA therapy was associated with higher SHBG, lower FAI and lower HOMA-IR values compared to women not on therapy (age and BMI-adjusted SHBG: CEE/MPA 148.8 nmol/l, controls 58.7 nmol/l, p < 0.01; age-adjusted FAI: CEE/MPA 0.8, controls 3.2, p < 0.05; age-adjusted HOMA-IR: CEE/MPA 1.3, controls 2.6, p < 0.05). On the contrary, E2/NETA treatment had no effect on these parameters. Women on tibolone had lower SHBG, higher FAI and similar HOMA-IR values compared to controls (age and BMI-adjusted SHBG: 24.1 nmol/l, p < 0.01; FAI: 6.0, p < 0.05; HOMA-IR: 2.3, p = NS). Raloxifene users did not exhibit any difference with respect to sex steroids and HOMA-IR levels. CONCLUSIONS: CEE/MPA users had lower free testosterone and improved insulin sensitivity. Tibolone on the other hand associated with higher free testosterone, while raloxifene did not relate to any of these parameters.     

Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate

Objectives: To assess differences in two sequential combined hormone replacement therapy (HRT) products on selected cardiovascular and breast metabolic markers. The products were different concerning the route of administration of estradiol and its combined progestin, either oral or transdermal, and the androgenic properties of progestogens, respectively, dydrogesterone and norethisterone acetate. Methods: One hundred and nineteen healthy non-hysterectomized postmenopausal women were included in this open, multi-center, two parallel group trial. They were randomized to a treatment of six 28-day cycles with oral estradiol sequentially combined with dydrogesterone (oE2/D10) or a sequential combination patch of estradiol plus norethisterone acetate (tdE/NETA). At baseline and after six cycles the high-density lipoprotein cholesterol (HDL-C), the sex hormone binding globulin (SHBG) and the total insulin-like growth factor-I (IGF-I) blood levels were determined by a central laboratory. A total of 89 women were compliant to the protocol. Results: After six cycles, a statistically significant difference (P<0.001) concerning HDL-C, SHBG and IGF-I levels was found between the two treatment groups. The HDL-C levels were increased in the oE2/D10 group and decreased in the tdE/NETA group, with a final difference of about 0.3 mmol/l. The oE2/D10 treatment induced a sharp increase (about 57 mmol/l) in SHBG levels. IGF-I levels decreased with both the products, but the difference in favor of the oE2/D10 treatment was of about 30 ng/ml. Moreover, patients on tdE/NETA with an IGF-I baseline value below the median showed an increase. Conclusion: Oral estradiol sequentially combined with dydrogesterone, a non-androgenic progestogen, induced positive changes of some cardiovascular (HDL-C) and breast (SHBG and IGF-I) metabolic markers. These effects were significantly different from those obtained with a transdermal estradiol associated to an androgenic progestogen.     

The effects of long-term low intensity aerobic training and detraining on serum lipid and lipoprotein concentrations in elderly men and women

The effects of long-term low intensity aerobic training and detraining on serum lipid and lipoprotein concentrations were examined in 30 elderly men and women. These subjects were randomly divided into two groups. The training group [n=15; 7 men and 8 women; mean age 75.5 (SD 5.6) years] agreed to take part in physical training using a treadmill with an exercise intensity at the blood lactate concentration threshold for 30 min 3–6 times a week for 9 months. The other group [n=15; 7 men and 8 women; mean age 73.7 (SD 4.4) years] did not perform any particular physical training and was followed as the control. Following this training period the high density lipoprotein-cholesterol (HDL-C) had increased significantly (P<0.01) while the total cholesterol (TC) : HDL-C ratio had decreased significantly (P<0.01) in the training group after 9 months but had not changed in the control group. The TC, triglyceride (TG) and low density lipoprotein-cholesterol (LDL-C) had not changed significantly in either group. No significant difference was seen between the groups throughout the period for TC, LDLC or TG. There was, however, a significant correlation between the initial TC:HDL-C ratio and the change in the TC:HDL-C ratio following 3 months of training (P <0.05). After 1 month of detraining in 5 patients, the HDL-C had decreased significantly (P < 0.05) while the TC:HDL-C had increased significantly in the training group (P<0.01). These results suggested that long-term low intensity aerobic training improved the profile of serum lipid and lipoprotein concentrations, while detraining returned the profile to that of the pretraining levels in elderly persons.     

补阳还五汤加减治疗冠心病对血脂和雌二醇代谢的影响

目的:探讨补阳还五汤加减治疗冠心病血脂和雌二醇(E2)代谢的变化。方法:49例冠心病患者服用补阳还五汤加减治疗两个月,应用酶法检测治疗前后的总胆固醇(TC)、甘油三脂(TG),均相酶法检测高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C),免疫透射比浊法检测载脂蛋白A1(ApoA1)和载脂蛋白B(ApoB),化学发光免疫法检测雌二醇(E2)。结果:治疗后TC、LDL-C、ApoB降低,ApoA1升高,与治疗前比较差异有显著性意义(P<0.05),TG、HDL-C、E2治疗前后比较无统计学差异(P>0.05)。结论:补阳还五汤加减治疗冠心病有助于改善血脂代谢。     

来曲唑对多囊卵巢综合征患者性激素结合球蛋白水平及糖脂代谢指标的影响

目的探究来曲唑(LE)对多囊卵巢综合征(PCOS)患者性激素结合球蛋白(SHBG)水平及糖脂代谢指标的影响。方法选取2016年6月至2019年6月本院诊治的80例PCOS患者为研究对象。根据非随机临床同期对照研究及患者自愿原则分为观察组、对照组,每组40例,对照组患者口服枸橼酸氯米芬片(初始剂量50 mg/d,无排卵反应后增至100mg/d)治疗,观察组给予LE(月经第5天口服LE,5 mg/d)治疗,两组均持续给药5 d,比较治疗前、疗程结束后两组糖脂代谢指标[总胆固醇(TC)、低密度脂蛋白(LDLC)、三酰甘油(TG)及空腹胰岛素(INS)、胰岛素抵抗指数(HOMA-IR)]、SHBG水平、性激素[卵泡生成素(FSH)、黄体生成素(LH)、雌二醇(E2)、睾酮(T)]水平、排卵、妊娠情况及药物安全性。结果与同组治疗前比较,疗程结束后两组TC、LDLC、TG、INS、HOMA-IR明显降低(P<0.05),且观察组INS、HOMA-IR明显低于对照组(P<0.05),与同组治疗前比较,疗程结束后两组SHBG、FSH明显升高、LH、E2、T明显降低,且观察组SHBG、FSH相较于对照组显著升高、LH、E2、T显著降低(P<0.05),观察组周期排卵率、临床妊娠率明显高于对照组(χ^2=4.228、4.073,P<0.05),观察组不良反应总发生率与对照组比较差异无统计学意义(P>0.05)。结论LE治疗PCOS患者的促排卵效果显著,可明显降低SHBG水平、调节性激素水平并提高临床妊娠率,而促排卵治疗前需指导应用抗雄激素药物、胰岛素增敏剂以有效调节患者的糖脂代谢指标。